Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation

Alessio Nencioni, Karin Schwarzenberg, Katharina M. Brauer, Susanne M. Schmidt, Alberto Ballestrero, Frank Grünebach, Peter Brossart

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Evidence from the animal model suggests that proteasome inhibitors may have immunosuppressive properties; however, their effects on the human immune system remain poorly investigated. Here, we show that bortezomib, a proteasome inhibitor with anticancer activity, impairs several immune properties of human monocyte-derived dendritic cells (DCs). Namely, exposure of DCs to bortezomib reduces their phagocytic capacity, as shown by FITC-labeled dextran internalization and mannose-receptor CD206 down-regulation. DCs treated with bortezomib show skewed phenotypic maturation in response to stimuli of bacterial (lipopolysaccharide [LPS]) and endogenous sources (including TNF-α and CD40L), as well as reduced cytokine production and immunostimulatory capacity. LPS-induced CCL-2/MCP-1 and CCL5/RANTES secretions by DCs were prevented by DC treatment with bortezomib. Finally, CCR7 up-regulation in DCs exposed to LPS as well as migration toward CCL19/MIP-3β were strongly impaired. As a suitable mechanism for these effects, bortezomib was found to down-regulate MyD88, an essential adaptor for TLR signaling, and to relieve LPS-induced activation of NF-κB, IRF-3, and IRF-8 and of the MAP kinase pathway. In summary, inhibition of DC function may represent a novel mechanism by which proteasome inhibitors exert immunomodulatory effects. These compounds could prove useful for tuning TLR signaling and for the treatment of inflammatory and immune-mediated disorders.

Original languageEnglish
Pages (from-to)551-558
Number of pages8
JournalBlood
Volume108
Issue number2
DOIs
Publication statusPublished - Jul 15 2006

Fingerprint

Proteasome Inhibitors
Dendritic Cells
Chemical activation
Lipopolysaccharides
Down-Regulation
Chemokine CCL5
CD40 Ligand
Fluorescein-5-isothiocyanate
Immune system
Immune System Diseases
Immunosuppressive Agents
Bortezomib
Monocytes
Immune System
Animals
Phosphotransferases
Up-Regulation
Animal Models
Tuning
Cytokines

ASJC Scopus subject areas

  • Hematology

Cite this

Nencioni, A., Schwarzenberg, K., Brauer, K. M., Schmidt, S. M., Ballestrero, A., Grünebach, F., & Brossart, P. (2006). Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood, 108(2), 551-558. https://doi.org/10.1182/blood-2005-08-3494

Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. / Nencioni, Alessio; Schwarzenberg, Karin; Brauer, Katharina M.; Schmidt, Susanne M.; Ballestrero, Alberto; Grünebach, Frank; Brossart, Peter.

In: Blood, Vol. 108, No. 2, 15.07.2006, p. 551-558.

Research output: Contribution to journalArticle

Nencioni, A, Schwarzenberg, K, Brauer, KM, Schmidt, SM, Ballestrero, A, Grünebach, F & Brossart, P 2006, 'Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation', Blood, vol. 108, no. 2, pp. 551-558. https://doi.org/10.1182/blood-2005-08-3494
Nencioni, Alessio ; Schwarzenberg, Karin ; Brauer, Katharina M. ; Schmidt, Susanne M. ; Ballestrero, Alberto ; Grünebach, Frank ; Brossart, Peter. / Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. In: Blood. 2006 ; Vol. 108, No. 2. pp. 551-558.
@article{31dc9f95f1754a3aa4f9ea21ce463da9,
title = "Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation",
abstract = "Evidence from the animal model suggests that proteasome inhibitors may have immunosuppressive properties; however, their effects on the human immune system remain poorly investigated. Here, we show that bortezomib, a proteasome inhibitor with anticancer activity, impairs several immune properties of human monocyte-derived dendritic cells (DCs). Namely, exposure of DCs to bortezomib reduces their phagocytic capacity, as shown by FITC-labeled dextran internalization and mannose-receptor CD206 down-regulation. DCs treated with bortezomib show skewed phenotypic maturation in response to stimuli of bacterial (lipopolysaccharide [LPS]) and endogenous sources (including TNF-α and CD40L), as well as reduced cytokine production and immunostimulatory capacity. LPS-induced CCL-2/MCP-1 and CCL5/RANTES secretions by DCs were prevented by DC treatment with bortezomib. Finally, CCR7 up-regulation in DCs exposed to LPS as well as migration toward CCL19/MIP-3β were strongly impaired. As a suitable mechanism for these effects, bortezomib was found to down-regulate MyD88, an essential adaptor for TLR signaling, and to relieve LPS-induced activation of NF-κB, IRF-3, and IRF-8 and of the MAP kinase pathway. In summary, inhibition of DC function may represent a novel mechanism by which proteasome inhibitors exert immunomodulatory effects. These compounds could prove useful for tuning TLR signaling and for the treatment of inflammatory and immune-mediated disorders.",
author = "Alessio Nencioni and Karin Schwarzenberg and Brauer, {Katharina M.} and Schmidt, {Susanne M.} and Alberto Ballestrero and Frank Gr{\"u}nebach and Peter Brossart",
year = "2006",
month = "7",
day = "15",
doi = "10.1182/blood-2005-08-3494",
language = "English",
volume = "108",
pages = "551--558",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation

AU - Nencioni, Alessio

AU - Schwarzenberg, Karin

AU - Brauer, Katharina M.

AU - Schmidt, Susanne M.

AU - Ballestrero, Alberto

AU - Grünebach, Frank

AU - Brossart, Peter

PY - 2006/7/15

Y1 - 2006/7/15

N2 - Evidence from the animal model suggests that proteasome inhibitors may have immunosuppressive properties; however, their effects on the human immune system remain poorly investigated. Here, we show that bortezomib, a proteasome inhibitor with anticancer activity, impairs several immune properties of human monocyte-derived dendritic cells (DCs). Namely, exposure of DCs to bortezomib reduces their phagocytic capacity, as shown by FITC-labeled dextran internalization and mannose-receptor CD206 down-regulation. DCs treated with bortezomib show skewed phenotypic maturation in response to stimuli of bacterial (lipopolysaccharide [LPS]) and endogenous sources (including TNF-α and CD40L), as well as reduced cytokine production and immunostimulatory capacity. LPS-induced CCL-2/MCP-1 and CCL5/RANTES secretions by DCs were prevented by DC treatment with bortezomib. Finally, CCR7 up-regulation in DCs exposed to LPS as well as migration toward CCL19/MIP-3β were strongly impaired. As a suitable mechanism for these effects, bortezomib was found to down-regulate MyD88, an essential adaptor for TLR signaling, and to relieve LPS-induced activation of NF-κB, IRF-3, and IRF-8 and of the MAP kinase pathway. In summary, inhibition of DC function may represent a novel mechanism by which proteasome inhibitors exert immunomodulatory effects. These compounds could prove useful for tuning TLR signaling and for the treatment of inflammatory and immune-mediated disorders.

AB - Evidence from the animal model suggests that proteasome inhibitors may have immunosuppressive properties; however, their effects on the human immune system remain poorly investigated. Here, we show that bortezomib, a proteasome inhibitor with anticancer activity, impairs several immune properties of human monocyte-derived dendritic cells (DCs). Namely, exposure of DCs to bortezomib reduces their phagocytic capacity, as shown by FITC-labeled dextran internalization and mannose-receptor CD206 down-regulation. DCs treated with bortezomib show skewed phenotypic maturation in response to stimuli of bacterial (lipopolysaccharide [LPS]) and endogenous sources (including TNF-α and CD40L), as well as reduced cytokine production and immunostimulatory capacity. LPS-induced CCL-2/MCP-1 and CCL5/RANTES secretions by DCs were prevented by DC treatment with bortezomib. Finally, CCR7 up-regulation in DCs exposed to LPS as well as migration toward CCL19/MIP-3β were strongly impaired. As a suitable mechanism for these effects, bortezomib was found to down-regulate MyD88, an essential adaptor for TLR signaling, and to relieve LPS-induced activation of NF-κB, IRF-3, and IRF-8 and of the MAP kinase pathway. In summary, inhibition of DC function may represent a novel mechanism by which proteasome inhibitors exert immunomodulatory effects. These compounds could prove useful for tuning TLR signaling and for the treatment of inflammatory and immune-mediated disorders.

UR - http://www.scopus.com/inward/record.url?scp=33745932074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745932074&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-08-3494

DO - 10.1182/blood-2005-08-3494

M3 - Article

C2 - 16537813

AN - SCOPUS:33745932074

VL - 108

SP - 551

EP - 558

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -